The ABHD15 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line. This product provides a heterogeneous pool of cells with targeted disruption of the ABHD15 gene, serving as a loss-of-function model for functional studies. The polyclonal format eliminates clonal selection, ensuring a representative cross-section of editing events while minimizing bias. These cells enable the investigation of ABHD15??s role in lipid metabolism and tumor cell biology without precise characterization of the editing mechanism.
A-549 cells are adherent epithelial cells originally isolated from a 58-year-old male patient with lung adenocarcinoma. They are extensively used as a model for type II alveolar basal epithelium and are instrumental in studying lung adenocarcinoma pathogenesis, including processes such as proliferation, apoptosis, and migration. The integration of ABHD15 knockout into this background creates a relevant system to explore how lipid metabolic enzymes influence cancer cell behavior within an alveolar epithelial context.
ABHD15 is a poorly characterized member of the ??/?? hydrolase superfamily, predicted to function as a lipid hydrolase involved in glycerophospholipid metabolism. Its enzymatic activity is thought to hydrolyze lysophospholipids and phospholipids, thereby modulating the levels of bioactive lipid signaling molecules. In A-549 cells, loss of ABHD15 may disrupt lipid hydrolysis, potentially altering downstream pathways that regulate cell proliferation and survival. Representative components linked to ABHD15 include lysophospholipids, phospholipids, and lipid signaling intermediates, though specific upstream regulators and downstream targets remain unknown.
This knockout model addresses a critical gap in understanding ABHD15??s contribution to lung adenocarcinoma, where lipid metabolism dysregulation is increasingly recognized. By coupling ABHD15 disruption with the A-549 cell line, researchers can assess phenotypic outcomes such as changes in proliferation rate, cell cycle progression, and apoptotic sensitivity. The polyclonal population facilitates robust, statistically meaningful assays, as the cellular heterogeneity mirrors biological variation, making it a powerful tool for initial functional screening.
Typical applications include lipidomic profiling to detect altered lipid species, proliferation assays (e.g., MTT or BrdU), cell cycle analysis using propidium iodide staining, and annexin V apoptosis assays. Western blotting and RT-qPCR confirm ABHD15 knockout and assess downstream effectors. Migration and invasion assays can evaluate metastatic potential. These cells are suited for cancer biology, lipid metabolism, and enzyme function studies. For further technical details, please contact Ascent Research.
